- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00953043
Lubiprostone, Colonic Motility and Sensation
The Effect of Lubiprostone, a Chloride Channel Activator, on Colonic Sensorimotor Functions in Healthy Subjects. A Phase IV, Placebo-Controlled, Parallel Group Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a trial of healthy adults to compare the effects of oral lubiprostone, 24 microgram per day and placebo for three days, on sensation and contractions of the colon using validated methods.
On days 1 and 2, participants took the study medication with their breakfast and recorded the time. On day 2 starting at 4:00 pm, participants started a polyethylene glycol-based bowel preparation to cleanse the colon. After overnight bowl preparation, participants reported fasting to the study center at 7:00 am on day 3. Colonic sensorimotor functions were assessed by an endoscopically placed barostat-manometric assembly.
After 30 minutes of rest following tube placement, fasting colonic tone, colonic compliance and colonic sensation were tested. The last dose of medication was ingested and 1 hour later the same colonic functions, as well as colonic response to a standardized meal of a 1,000-kilocalorie chocolate milkshake were assessed. The participant was able to leave the study center in the afternoon, after a meal had been ingested (if desired).
Details on colonic tube placement: A flexible sigmoidoscopy was performed to evaluate the left side of the colon and to place a Teflon-coated guide wire beyond the splenic flexure. The colon was deflated as the sigmoidoscope was removed and a barostat catheter (constructed at Mayo Clinic, Rochester, MN) with six manometric point sensors and a polyethylene balloon was introduced into the colon over the guide wire. The barostat catheter was positioned in the mid-descending or upper sigmoid colon with the aid of fluoroscopy. The final position of the barostatically controlled balloon was confirmed by fluoroscopy. After the colonic tube placement, participants rested for 30 min. The catheter was connected to a rigid piston barostat machine. After transient inflation of the barostat bag to a volume of 75 ml to ensure it was unfolded, it was deflated. Thereafter, it was inflated in 2 mm Hg increments to baseline operating pressure, which was defined as 2 mm Hg above the minimal distension pressure at which respiratory excursions were clearly recorded by the barostat tracing.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Healthy subjects
- Body mass index (BMI): 18 to 32.
- Negative pregnancy test for women of childbearing potential.
- Absence of gastrointestinal symptoms (abridged Bowel Disease Questionnaire).
- Signed informed consent.
Exclusion criteria:
- Subjects with body mass index (BMI) of less than 18 or more than 32.
- Structural or metabolic diseases/conditions that affect the gastrointestinal (GI)system, or functional gastrointestinal disorders. For screening, the Bowel Disease Questionnaire will be used to exclude subjects with irritable bowel syndrome.
- Use of drugs or agents within the past 2 weeks that alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, SSRI and newer antidepressants.
NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection, and birth control pills or depot injections are permissible.
- Use of drugs or agents within the 2 weeks prior to screening that may add drowsiness and central nervous system (CNS) depression such as barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants.
- Female subjects who are pregnant or breast feeding.
- Females must be either surgically sterilized, postmenopausal (>12 months since last menses) or, if of childbearing potential, using reliable methods of contraception as determined by the physician (single-barrier methods alone and rhythm methods are not acceptable).
- Clinical evidence (including physical exam and ECG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Any candidate participants with such disorder mentioned will be referred to their general physician.
- The Hospital Anxiety and Depression Scale (HADS) will be used to exclude subjects with significant affective disorders, as well as to determine anxiety and depression scores at the start of the study. Any candidate participants with such disorder mentioned will be referred to their general physician.
- Symptoms of a significant clinical illness in the two weeks prior to screening.
- Participation in another clinical study within the 30 days prior to screening.
- Subjects who are considered by the investigator to be alcoholics not in remission or known substance abusers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Lubiprostone
Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
|
Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
Other Names:
Polyethylene glycol-based bowel preparation
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Subjects randomized to this arm received placebo medication for three days.
|
Polyethylene glycol-based bowel preparation
Other Names:
Placebo medication given for three days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonic Compliance
Time Frame: 1 hour after third dose of lubiprostone or placebo, on Day 3
|
Colonic compliance is a measure of the "stiffness" of the colon, that is, what pressure was needed to reach half the maximum volume of the colon. After the barostat catheter was inserted in the colon, the catheter was connected to a barostat machine. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg up to 64 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance. |
1 hour after third dose of lubiprostone or placebo, on Day 3
|
Fasting Colonic Tone
Time Frame: 30 minutes after the colonic tube placement, on Day 3
|
Colonic tone is a measurement of the volume of the colon.
Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon).
|
30 minutes after the colonic tube placement, on Day 3
|
Postprandial Colonic Tone
Time Frame: 30 minutes after standard meal, on Day 3
|
Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon).
|
30 minutes after standard meal, on Day 3
|
Pain Sensation Ratings in Response to Colonic Distension at 32 mm HG Above Baseline Operating Pressure
Time Frame: approximately 1 hour after colonic tube placement, on Day 3
|
Pain was measured by a 100 mm long Visual Analog Scale (VAS).
The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain.
The investigator measures the mark made by the participant in mm and records this for the value of pain.
|
approximately 1 hour after colonic tube placement, on Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gas Sensation Ratings in Response to Colonic Distensions at 32 mm Hg Above Baseline Operating Pressure
Time Frame: approximately 1 hour after colonic tube placement, on Day 3
|
Gas sensation was measured by a 100 mm long Visual Analog Scale (VAS).
The VAS does not have any pre-set marks between the extremes of 0 for no gas sensation and 100 mm for extreme gas sensation.
The investigator measures the mark made by the participant in mm and records this for the value of gas sensation.
|
approximately 1 hour after colonic tube placement, on Day 3
|
Median Pressure When First Sensation Was Reported by 50% of Participants
Time Frame: approximately 45 min after colonic tube placement, on Day 3
|
The sensory threshold for first sensation was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg.
During this assessment participants were asked to report when they had the first sensation.
The investigator recorded the threshold pressure at which the participants reported this sensation.
|
approximately 45 min after colonic tube placement, on Day 3
|
Median Pressure When Gas Sensation Was First Reported by 50% of Participants
Time Frame: approximately 45 min after colonic tube placement, on Day 3
|
The sensory threshold for first perception of gas was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg.
During this assessment participants were asked to report when they had the first perception of gas.
The investigator recorded the threshold pressure at which the participants reported this sensation.
|
approximately 45 min after colonic tube placement, on Day 3
|
Median Pressure When Pain Sensation Was First Reported by 50% of Participants
Time Frame: approximately 45 min after colonic tube placement, on Day 3
|
The sensory threshold for first perception of pain was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg.
During this assessment participants were asked to report when they had the first perception of pain.
The investigator recorded the threshold pressure at which the participants reported this sensation.
|
approximately 45 min after colonic tube placement, on Day 3
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-001438
- UL1RR024150 (U.S. NIH Grant/Contract)
- R01DK054681 (NIH)
- K24DK002638 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on lubiprostone
-
Sucampo Pharma Americas, LLCTakedaCompletedHealthy VolunteersUnited States
-
Baylor College of MedicineUniversity of South FloridaCompletedParkinson's DiseaseUnited States
-
Texas Tech University Health Sciences Center, El...Completed
-
Dartmouth-Hitchcock Medical CenterTakeda Pharmaceuticals North America, Inc.CompletedChronic Idiopathic ConstipationUnited States
-
University of ArkansasTakeda Pharmaceuticals North America, Inc.CompletedConstipation | Cystic FibrosisUnited States
-
Helwan UniversityCompleted
-
University of South AlabamaTakeda; Sucampo Pharmaceuticals, Inc.TerminatedConstipationUnited States
-
Brooke Army Medical CenterTakedaCompletedBowel Preparation for ColonoscopyUnited States
-
Henry Ford Health SystemTakeda Pharmaceuticals North America, Inc.CompletedColonoscopyUnited States
-
Sucampo Pharma Americas, LLCCompletedOpioid-Induced Bowel DysfunctionUnited States, Canada